EUVIMEDEUVIMED entdecken
Crossref

Treatment-shift from primary surgery to radiotherapy for stage T1b cervical cancer in the United States

M. Klar, M. W. Lee, E. Yu, S. Matsuzaki, K. Matsuo

Geburtshilfe und Frauenheilkunde · 01.10.2024 · 84 (10) · e161

DOI: 10.1055/s-0044-1790809 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Geburtshilfe und Frauenheilkunde, erschienen am 01.10.2024. Verfasst von M. Klar und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess temporal trends of primary treatment approach for stage T1b cervical cancer in the United States.

Methods

This retrospective cohort study queried the National Cancer Institute's Surveillance, Epidemiology, and End Results Program. Study population was 11,706 patients with AJCC T1b/N0-1/M0 cervical cancer who received primary anti-cancer treatment either with hysterectomy or definitive radiotherapy without hysterectomy from 2004-2021. Linear segmented regression with log-transformation was used to assess primary treatment per one-year increments. Exploratory analysis included survival association for primary therapy.

Results

The most frequent tumor size was ≤2cm ( n =4,763, 40.7%), followed by 2.1-4cm ( n =4,203, 35.9%) and >4cm ( n =2,740, 23.4%). Among node-metastasis cases, use of primary radiotherapy increased in all three size groups from 2004-2021 (≤2cm, 13.1% to 41.1%; 2.1-4cm, 15.2% to 52.2%; >4cm, 36.7% to 85.2%, all, P 4cm from 2010-2021 (44.6% to 68.8%, P=.002) whereas primary hysterectomy remained the majority in size ≤2cm (93.5% to 89.4%) and 2.1-4cm (83.4% to 81.5%) groups (both, P >.05). Primary hysterectomy was associated with improved survival in all subgroups except for node-metastatic size >4cm where these two modalities had comparable survival.

Conclusion

The results of current population-based assessments suggest that primary treatment for stage T1b cervical cancer is gradually shifting from hysterectomy to radiotherapy in the United States when nodes are involved despite smaller tumor size of ≤2cm or 2.1-4cm. This real-world practice data suggests possible prognostic role of primary hysterectomy in tumor size ≤4cm even nodes are involved, warranting further evaluation. Publication History Article published online: 01 October 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Klar, M., Lee, M. W., Yu, E., Matsuzaki, S., & Matsuo, K. (2024). Treatment-shift from primary surgery to radiotherapy for stage T1b cervical cancer in the United States. Geburtshilfe und Frauenheilkunde, 84(10), e161. https://doi.org/10.1055/s-0044-1790809

Vancouver

Klar M, Lee MW, Yu E, Matsuzaki S, Matsuo K. Treatment-shift from primary surgery to radiotherapy for stage T1b cervical cancer in the United States. Geburtshilfe und Frauenheilkunde. 2024;84(10):e161. doi:10.1055/s-0044-1790809

BibTeX
@article{Klar2024,
  author = {Klar, M. and Lee, M. W. and Yu, E. and Matsuzaki, S. and Matsuo, K.},
  title = {Treatment-shift from primary surgery to radiotherapy for stage T1b cervical cancer in the United States},
  journal = {Geburtshilfe und Frauenheilkunde},
  year = {2024},
  volume = {84},
  number = {10},
  pages = {e161},
  doi = {10.1055/s-0044-1790809}
}
Kostenlos starten →